Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis.

Kenichi NakamuraKeiichi HatakeyamaKenichiro FurukawaKeiichi FujiyaSatoshi KamiyaMakoto HikageYutaka TanizawaEtsuro BandoKeiichi OhshimaKenichi UrakamiNozomu MachidaHirofumi YasuiKen YamaguchiMasanori Terashima

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)

The upregulation and enrichment of immune-related genes and GO terms may be predictive biomarkers in patients who would benefit from adjuvant S-1 chemotherapy to treat Stage II/III gastric cancer.

Keyphrases

gene expression
early stage
dna methylation
poor prognosis
cell proliferation
signaling pathway
combination therapy
long non coding rna